Skip to main content
SpringerLink
Log in
Book cover

Mammakarzinom Interdisziplinär pp 174–197Cite as

Systemische Therapie

  • Chapter

  • 2579 Accesses

Zusamenfassung

Die neoadjuvante (primäre) systemische Therapie umfasst alle medikamentösen Therapieformen, die nach histologischer Diagnosestellung eines Mammakarzinoms vor Durchführung der operativen Maßnahmen verabreicht werden.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   29.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   79.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Bear HD, Mamounas P, Wolmark N et al. (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 21(22): 4165–74

    Article  CAS  PubMed  Google Scholar 

  • Buzdar AU, Hunt K, Smith T et al. Significantly higher pathological complete remission (pCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P) and anthracycline containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. Proc AM Soc Clin Oncol 2004: Abstr. 520

    Google Scholar 

  • Denkert C, Loibl S, Noske A et al (2009) Tumor-associated lymphocytes as an independent predictor of response to neo-adjuvant chemotherapy in breast cancer. J Clin Oncol [Epub ahead of print]

    Google Scholar 

  • Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG et al. (1997) Effect of preoperative chemotherapy on localregional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483–9

    CAS  PubMed  Google Scholar 

  • Gianni L, Baselga J, Eiermann W et al. (2005) European Cooperative Trial in Operable Breast Cancer Study Group: Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 11(24 Pt1): 8715–21

    Article  CAS  PubMed  Google Scholar 

  • Gianni L, Eiermann W, Semiglazov V et al. (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375: 377

    Article  CAS  PubMed  Google Scholar 

  • Kaufmann M, von Minckwitz G, Bear HD et al. (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18(12): 1927–34

    Article  CAS  PubMed  Google Scholar 

  • Untch M, Fasching PA, Stöckl D et al. (2008) PREPARE trial. A randomized phase III trial comparing preoperative, dose dense, doseintensified chemotherapy with epirubicin, paclitaxel and CMF with standard dosed epirubicin/cyclophosphamide followed by paclitaxel darbepoetin alfa in primary breast cancer: a preplanned interim analysis of efficacy at surgery. J Clin Oncol 26 (suppl), Abstr. 517

    Google Scholar 

  • Untch M, Kaufmann M, Hilfrich J (2009) Lapatinib can safely be Given concomitant to EC-T as neoadjuvant chemotherapy for breast cancer. First planned safety analysis of the Geparquinto study (GBG 44), SABCS 2009, Abstr. 1094

    Google Scholar 

  • Untch M, Mobus V, Kuhn W et al. (2009) Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol 27: 2938–2945

    Article  PubMed  Google Scholar 

  • Untch M, Rezai M, Loibl S et al. Neoadjuvant treatment of HER2 overexpressingvprimary breast cancer with trastuzumab given concomitantly to epirubicin/ cyclophosphamide followed by docetaxel and capecitabine. First analysis of efficacy and safety of the GBG/AGO multicenter intergroup-study »GeparQuattro«. Eur J Cancer 2008;(Suppl 6): Abstr. 47

    Google Scholar 

  • Untch M, Rezai M, Loibl S et al. (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro Study. J Clin Oncol, accepted for publication

    Google Scholar 

  • Untch M, Stoeckl D, Konecny G et al. (2005) A multicenter phase II study of preoperative epirubicin, cyclophosphamide (EC) followed by paclitaxel (P) plus trastuzumab (T) in Her2 positive primary breast cancer. Breast Cancer Res Treat 94 (Suppl 1): Abstr 1064

    Google Scholar 

  • Von Minckwitz G, Kaufmann M, Kümmel S et al. (2009) Integrated metaanalysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane±Trastuzumab containing chemotherapy. Cancer Res 69 (Suppl. 2): Abstr. 79

    Google Scholar 

  • Von Minckwitz G, Kümmel S, Vogel P et al. for the German Breast Group (2008) Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst 100: 542–551

    Google Scholar 

  • Von Minckwitz G, Raab G, Caputo A et al. (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23(12): 2676–2685

    Article  Google Scholar 

  • von Minckwitz G, Rezai M, Loibl S et al. (2010) Capecitabine in addition to anthracycline/taxane-based neoadjuvant treatment in patients with primary breast cancer: the phase III GeparQuattro Study. J Clin Oncol, accepted for publication

    Google Scholar 

  • Wöckel A, Kreienberg R (2008) First Revision of the German S3 Guideline «Diagnosis, Therapy, and Follow-Up of Breast Cancer«. Breast Care 3: 82–86

    Article  Google Scholar 

  • Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2003) Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from national surgical adjuvant breast and bowel project B-18. Journal of the National Cancer Institute Monographs 30: 96–102

    Google Scholar 

Literatur

  • Albain KS, Barlow WE, Ravdin PM et al. (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374: 2055–63

    Article  PubMed  Google Scholar 

  • Bonadonna G, Valagussa, P, Moliterni A, Zambetti M et al. (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. N Engl J Med 332: 901–906

    Article  CAS  PubMed  Google Scholar 

  • Bonadonna G, Moliterni A, Zambetti M et al (2005) 30 years’ follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ Jan 29; 330(7485): 217

    Article  PubMed  Google Scholar 

  • Bonneterre J, Roche H, Kerbrat P, Bremond A et al. (2005) Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 23(12): 2686–93

    Article  CAS  PubMed  Google Scholar 

  • Bria E, Nistico C, Cuppone F et al. (2006) Benefit of taxanes as adjuvant chemotherapy for early breast cancer. Cancer 106: 2337–44

    Article  CAS  PubMed  Google Scholar 

  • Budman DR, Berry DA, Cirrincione CT, Henderson IC et al. (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer I 90: 1205–1211

    CAS  Google Scholar 

  • Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431–1439

    Article  CAS  PubMed  Google Scholar 

  • Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Cold S, Edlund P (2007) Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur J Cancer 43: 877–84

    Article  CAS  PubMed  Google Scholar 

  • Fisher B, Brown AM, Dimitrov NV et al. (1990) Two months of doxorubicin-cyclophosphamide with and without reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifennonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8: 1483–1496

    CAS  PubMed  Google Scholar 

  • Fisher B, Jeong J-H, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N (2004) Treatment of lymph-node-negative, oestrogenreceptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. The Lancet 364: 858–868

    Article  CAS  Google Scholar 

  • Goldhirsch A, Ingle JN, Gelber RD et al. (2009) Tresholds for therapies: highlights oftheSt Gallen International Export Consensus on the Primary Therapy of Early Breast Cancer 2009. Annals of Oncology 20: 1319–1329

    Article  CAS  PubMed  Google Scholar 

  • Hryniuk W, Levine MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4: 1162–1170

    CAS  PubMed  Google Scholar 

  • Hudis C, Citron M, Berry D, Cirrincione C, Gradishar W, Davidson N et al. (2005) Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective. Breast Cancer Res and Treat 94(suppl 1): 41 (abstr.)

    Google Scholar 

  • Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R et al. (2009) Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet 10: 1145–51

    Article  CAS  Google Scholar 

  • Jones S, Holmes FA, O’Shaughnessy J et al (2009) Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with Doxorubicin and Cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735, J Clin Oncol 27: 1177–83

    Article  CAS  PubMed  Google Scholar 

  • Levine MN, Pritchard KI, Bramwell VH, Shepherd LE et al. (2005) Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 23(22): 5166–5170

    Article  CAS  PubMed  Google Scholar 

  • Martin M, Pienkowski T, Mackey J, Pawlicki M et al. for the Breast Cancer International Research Group 001 Investigators (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352: 2302–2313

    Google Scholar 

  • Martin M, Iluch A, Segui M et al. (2008) Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing tac with fac: 5-year efficacy analysis of the GEICAM 9805 trial. J Clin Oncol 26 (Suppl): 542 (abstract)

    Article  Google Scholar 

  • Möbus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C et al. (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: Mature results of an AGO-phase-III study. J Clin Oncol (2010) in press

    Google Scholar 

  • Muss HB, Berry DA, Cirrincione CT et al. (2009) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 260: 2055–65

    Article  Google Scholar 

  • Nitz U, Huober J, Lisboa B, Harbeck N, Fischer H, Moebus V et al. (2009) Superiority of sequential docetaxel over standard FE100C in patients with intermediate risk breast cancer: survival results of the randomized intergroup phase III trial EC-Doc. Cancer Res 69 (suppl; abstr 78)

    Google Scholar 

  • Piccart MJ, Di Leo A, Beauduin M et al. (2001) Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 19: 3103–3110

    CAS  PubMed  Google Scholar 

  • Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve R, Spooner D, Agrawall RK et al. for the NEAT Investigators and the SCTBG (2006) Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer. N Engl J Med 355: 1851–62

    Google Scholar 

  • Poole CJ, Hiller L, Howard HC, Dunn JA, Canney P, Wardley AM et al. (2008) tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy (CT) for women with early-stage breast cancer (EBC). J Clin Oncol 26: (suppl; abstr. 506)

    Google Scholar 

  • Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D et al. (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients. The FNCLCC PACS 01 Trial. J Clin Oncol 24: 5664–5671

    Article  PubMed  Google Scholar 

  • Sparano JA, Wang M, Martino S et al. (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358: 1663–71

    Article  CAS  PubMed  Google Scholar 

Literatur

  • Aebi S, Gelber S, Castiglione-Gertsch M et al. (2000) Is chemotherapy alone adequate for young women with oestrogen-receptorpositive breast cancer. Lancet 355: 1869–1874

    Article  CAS  PubMed  Google Scholar 

  • Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma; Suggestions for a new method of treatment with illustrative cases. Lancet 2: 104–107

    Article  Google Scholar 

  • Coombes RC et al. (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years’tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561): 559–70. Erratum in: Lancet 369(9565): 906

    Article  CAS  PubMed  Google Scholar 

  • Dowsett M (2003) Analysis of time to recurrence in the ATAC trial according to estrogen and progesterone receptor status. Breast Cancer Res Treat 82 [Suppl 1 ]: 3

    Google Scholar 

  • Goldhirsch A, Wood WC, Gelber RD et al. (2003) Meeting highlights: update international experts consensus on the primary therapy of early breast cancer. J Clin Oncol 21: 3357–3365

    Article  PubMed  Google Scholar 

  • Goss PE, Ingle JN, Martino S et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19): 1793–1802

    Article  CAS  PubMed  Google Scholar 

  • Jakesz R, Hausmaninger H, Kubista E et al. (2002) Adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormoneresponsive breast cancer — Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20: 4621–4627

    Google Scholar 

  • Jonat W, Kaufmann M, Sauerbrei W et al. (2002) Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Ocol 20: 4628–35

    Article  CAS  Google Scholar 

  • Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HAT, Andersen PK, Melbye M (2000) Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 320(7233): 474–478

    Article  CAS  PubMed  Google Scholar 

  • Del Mastro L, Venturini M, Sertoli MR, Rosso R (1997) Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat 2: 183–190

    Google Scholar 

  • Powles TJ, Hickish T, Kanis JA (1996) Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiomety in healthy premenopausal and postmenopausal women. J Clin Oncol 14: 78–84

    CAS  PubMed  Google Scholar 

Literatur

  • Benz CC et al. (1993) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Rest Treat 24(2): 85–95

    Article  CAS  Google Scholar 

  • Bolat F et al. (2006) Microvessel density, VEGF expression, and tumor-associated macrophages in breast tumors: correlations with prognostic parameters. J Exp Clin Cancer Res 25(3): 365–372

    CAS  PubMed  Google Scholar 

  • Dadparvar S et al. (2002) Thallium-201 imaging in evaluation of Hodgkins disease. Cancer J 8(6): 469–475

    Article  PubMed  Google Scholar 

  • Geyer CE et al. (2007) Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. N Engl J Med 356(14): 1487

    Google Scholar 

  • Holbro T et al. (2003) The ErbB receptors and their role in cancer progression. Exp Cell Res 284(1): 99–110

    Article  CAS  PubMed  Google Scholar 

  • Knuefermann C et al. (2003) HER2/PI-3k/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22(21): 3205–3212

    Article  CAS  PubMed  Google Scholar 

  • Kunisue H et al. (2000) Anti-HER2 antibody enhance the growth inhibitpry effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br J Cancer 82(1): 46–51

    Article  CAS  PubMed  Google Scholar 

  • Marty M et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265–4274

    Article  CAS  PubMed  Google Scholar 

  • Miller K et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357(26): 2666–2676

    Article  CAS  PubMed  Google Scholar 

  • O’Rourke et al. (2009) First-line lapatinib combined with letrozole versus letrozole alone for hormone receptor positive (HR+) metastatic breast cancer (MBC): Subgroup analyses of borderline FISH+, IHC 2+, HER2 unknown (UNK), and treatment-naive (TN) populations from EGF30008. J Clin Oncol 27: 15s, suppl;abstr. 1062

    Article  Google Scholar 

  • Padhy LC et al. (1982) Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 28(4): 865–871

    Article  CAS  PubMed  Google Scholar 

  • Slamon DJ et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–791

    Article  CAS  PubMed  Google Scholar 

  • Weidner N et al. (1991) Tumor angiogenesis and metastasis — correlation in invasive breast carcinoma. N Engl J Med 324(1): 1–8

    Article  CAS  PubMed  Google Scholar 

  • Yakes FM et al. (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62(14): 4132–4141

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Gynäkologie und Geburtshilfe HELIOS Klinikum, Schwanebecker Chaussee 50, 13125, Berlin

    Prof. Dr.med. Michael Untch

  2. Klinik für Gynäkologie und Geburtshilfe Klinikum Frankfurt Hoechst GmbH, Gotenstraße 6-8, 65929, Frankfurt/Höchst

    Prof. Dr.med. Volker Möbus

  3. Frauenklinik Universitätsklinikum Düsseldorf, Moorenstraße 5, 40225, Düsseldorf

    Prof. Dr.med. Wolfgang Janni

  4. Frauenklinikfür Gynäkologie u.Geburtsmedizin, Universitätsklinikum Aachen, Pauwelsstraße30, 52074, Aachen

    Prof. Dr.med. Nicolai Maass

  5. Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Arnold-Heller-Straße 3, 24105, Kiel

    Dr.med. Corinna Crohns

  6. Frauenklinik Universitätsklinikum Erlangen, Universitätsstraße 21-23, 91054, Erlangen

    Prof. Dr.med. Peter Fasching

  7. Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Michaelisstraße 16, 24105, Kiel

    Prof. Dr.med. Christoph Mundhenke

  8. Klinikfür Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Arnold-Heller-Straße 3, 24105, Kiel

    Prof. Dr.med. Walter Jonat

  9. Frauenheilkunde und Geburtshilfe, Universitätsklinikum Ulm, Prittwitzstraße43, 89075, Ulm

    Daniel Herr & Prof. Dr.med. Rolf Kreienberg

Authors
  1. Prof. Dr.med. Michael Untch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr.med. Volker Möbus
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr.med. Wolfgang Janni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prof. Dr.med. Nicolai Maass
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dr.med. Corinna Crohns
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Prof. Dr.med. Peter Fasching
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Prof. Dr.med. Christoph Mundhenke
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Prof. Dr.med. Walter Jonat
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Daniel Herr
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Prof. Dr.med. Rolf Kreienberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg New York

About this chapter

Cite this chapter

Untch, M. et al. (2010). Systemische Therapie. In: Mammakarzinom Interdisziplinär. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12681-9_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-12681-9_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-12680-2

  • Online ISBN: 978-3-642-12681-9

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation